Nuwellis Reveals Aquadex System Success in Liver Disease
Company Announcements

Nuwellis Reveals Aquadex System Success in Liver Disease

Nuwellis (NUWE) has released an update.

Nuwellis, Inc. has announced significant findings showing the effectiveness of their Aquadex SmartFlow® system for patients with severe liver disease experiencing fluid overload. The press release detailing these results emphasizes the system’s potential benefits, marking a noteworthy development in the treatment of end-stage liver disease related complications.

For further insights into NUWE stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyNuwellis to sell 469,340 shares at $4.24 in registered direct offering
GlobeNewswireNuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswireNuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!